CA Patent

CA3020393A1 — Chiral peptides

Assigned to Carnot LLC · Expires 2017-10-19 · 9y expired

What this patent protects

The present disclosure provides certain chiral peptide agents, and uses relating thereto.

USPTO Abstract

The present disclosure provides certain chiral peptide agents, and uses relating thereto.

Drugs covered by this patent

elamipretide-hydrochloride (ELAMIPRETIDE HYDROCHLORIDE)

Patent Metadata

Patent number: CA3020393A1
Jurisdiction: CA
Classification: —
Expires: 2017-10-19
Drug substance claim: No
Drug product claim: No
Assignee: Carnot LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.